Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Recommendation of “Buy” by Brokerages

Perspective Therapeutics, Inc. (NYSE:CATX) has been given a consensus recommendation of “Buy” by the ten brokerages that are presently covering the stock, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy rating. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $20.63.

Several research firms have issued reports on CATX. Oppenheimer reissued an “outperform” rating and set a $22.00 target price on shares of Perspective Therapeutics in a research note on Friday, October 11th. UBS Group began coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Wedbush reissued an “outperform” rating and issued a $20.00 price target on shares of Perspective Therapeutics in a research note on Thursday, October 24th. Finally, Royal Bank of Canada lowered their price objective on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a research report on Friday, August 16th.

Perspective Therapeutics Stock Performance

NYSE CATX opened at $11.05 on Tuesday. The business’s fifty day moving average is $13.09. Perspective Therapeutics has a 52 week low of $2.20 and a 52 week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.04. The firm had revenue of $0.53 million during the quarter. Sell-side analysts expect that Perspective Therapeutics will post -0.87 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in CATX. Hills Bank & Trust Co purchased a new position in Perspective Therapeutics in the third quarter worth approximately $13,722,000. Nicholson Wealth Management Group LLC purchased a new stake in shares of Perspective Therapeutics during the 3rd quarter worth $21,390,000. WealthPLAN Partners LLC acquired a new position in shares of Perspective Therapeutics during the second quarter worth $1,695,000. Bank of New York Mellon Corp increased its holdings in Perspective Therapeutics by 214.0% in the second quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock valued at $1,369,000 after buying an additional 93,548 shares during the last quarter. Finally, WINTON GROUP Ltd acquired a new stake in Perspective Therapeutics in the second quarter valued at $841,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.